Capital Ventech II Net Worth & Insider Trades

Capital Ventech II Eyegate Pharmaceuticals Inc

As of March 21, 2017

What is Capital Ventech II's Net Worth?

The current estimated net worth of Eyegate Pharmaceuticals Inc's Capital Ventech II is estimated to be about $5.05M . Capital Ventech II owns about 1,431,814 units of Eyegate Pharmaceuticals Inc common stock. In the last year at Eyegate Pharmaceuticals Inc, Capital Ventech II has sold an estimated value of $194.66K worth.

What is Capital Ventech II's Past Insider Trading?

Capital Ventech II's largest sale order was 29,400 units , worth over $95.42K on June 9, 2016. In total, Capital Ventech II has made about 3 transactions over a year of their time at Eyegate Pharmaceuticals Inc. Capital Ventech II usually trades in June, with the busiest year in 2016. The most recent transaction was a sale order of 4,419 units , worth over $12.38K on March 21, 2017.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What is Capital Ventech II's' Mailing Address?

  • Mailing address is 47 Avenue de L?opera Paris I0 75002 France

Eyegate Pharmaceuticals Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Compensation
Total
Stephen From 2020 $400,000 $160,000 $129,282 $193,923 - $883,205
Stephen From 2019 $400,000 $106,600 - $94,740 - $601,340
Sarah Romano 2020 $264,361 $60,000 $64,641 $64,641 - $453,643
Sarah Romano 2019 $250,000 $86,010 - $23,685 - $359,695
Michael Manzo 2020 $250,000 $60,000 $48,481 $48,481 - $406,962
Michael Manzo 2019 $250,000 $94,167 - $23,685 - $367,852
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1372514/000110465921058990/tm2114484-1_def14a.htm

What are Eyegate Pharmaceuticals Inc's Past Insider Trades?

Eyegate Pharmaceuticals Inc's most recent insider trade came on August 3, 2021 by Armistice Capital Llc, Armistice Capital Master Fund Ltd and Steven Boyd who sold 260,963 units worth $646.61K . In the last 6 years, insiders at Eyegate Pharmaceuticals Inc have sold an estimated value of $15.73M and bought an estimated value of $20.29M worth of shares. Insider trading is most common in February, with the busiest year in 2020. The most active traders at the company are Stephen From, Executive Chairman,  Michael Manzo, VP Engineering,  and Brenda Mann, VP Research & Development .

EYEGATE PHARMACEUTICALS INC Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1